Clinical Trials Directory

Trials / Unknown

UnknownNCT01850095

The Influence of Peripheral Androgen Conversion at Women Adult Acne

The Influence of Peripheral Androgen Conversion at Toll-like Receptors-2 and CD1d Expressions in Human Keratinocytes as Well as Their Modulation After 6 Months Treatment With Oral Contraceptive.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Marco Alexandre Dias da Rocha · Academic / Other
Sex
Female
Age
26 Years – 44 Years
Healthy volunteers
Accepted

Summary

Acne vulgaris is a chronic inflammatory disease that affects the pilosebaceous unit. Recent studies have demonstrated an increase number of acne cases in adult women. These cases are predominantly normoandrogenic and have some clinical differences when compared with the most common group, the adolescent. The local glandular metabolism converts some hormonal precursors to more active substances that increase the sebum production, leaving these areas more prone to increase the colonization to Propionibacterium Acnes (P. Acnes). Toll-like receptor 2, expressed by inflammatory cells play a crucial role in the innate immune response to this bacterium. Previous studies confirm that exist a reduced expression of CD1d by keratinocytes in acne lesion, what can be interpreted as a low antigen-present function. The influence of hormonal alteration in the sebaceous glands could modulate the expressions of TLR-2 and CD1d explaining the persistence of lesions in adult women. The change to more estrogenic metabolism, with use of specific contraceptive pills could normalize this immune-mediated inflammatory process. Objective To analyze how the peripheral androgen conversion can influence the toll-like receptor 2 and CD1d expression in women with inflammatory acne before and after 6 months of oral contraceptives with anti-androgen activity.

Conditions

Interventions

TypeNameDescription
DRUGtreatment azelaic acid (azelan)treatment for 6 months
DRUGdorspirenone/ethynil estradiol

Timeline

Start date
2012-03-01
Primary completion
2013-06-01
Completion
2015-01-01
First posted
2013-05-09
Last updated
2013-05-09

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01850095. Inclusion in this directory is not an endorsement.